Here's a clear breakdown of Establishment Labs' (ESTA) 2026 Proxy Statement (DEF 14A), focusing on what shareholders need to know:

🗳️ What This Document Is

This is the Definitive Proxy Statement (DEF 14A) for Establishment Labs' 2026 Annual Shareholder Meeting. It provides details on the proposals shareholders will vote on and essential company governance information. Think of it as the official agenda and info packet for the virtual meeting on May 22, 2026, at 1:00 PM Eastern Time.

🏢 What The Company Does

👉 In simple terms: Establishment Labs is a medical device company focused on breast aesthetics and reconstruction. They develop, manufacture, and sell silicone breast implants (like their Motiva Implants®) and related products. They operate globally, competing in the aesthetic and reconstructive surgery market.

🗓️ Key Meeting Details

Date & Time: Friday, May 22, 2026, at 1:00 PM Eastern Time
Location: Virtual Only via live audio webcast at www.virtualshareholdermeeting.com/ESTA2026
Record Date: Shareholders owning shares on April 2, 2026, get to vote.
How to Vote: Internet (www.proxyvote.com), telephone (1-800-690-6903), mail, or live during the virtual meeting.
Quorum Needed: Over 50% of shares entitled to vote must be present.

📋 What Shareholders Are Voting On (The Proposals)

ELECT DIRECTORS: Vote "FOR" or "AGAINST" each of the six nominees to serve until the 2027 annual meeting.
APPROVE EXECUTIVE COMPENSATION (Advisory): Vote "FOR" or "AGAINST" on approving the pay of the top executives (Named Executive Officers - NEOs). This is non-binding but influential.
RATIFY AUDITORS: Vote "FOR" or "AGAINST" to appoint CBIZ CPAs P.C. as the independent auditor for the fiscal year ending December 31, 2026. (Routine matter).

👉 Board Recommendation: The Board of Directors recommends shareholders vote "FOR" all three proposals.

👥 The Director Nominees (Proposal 1)

The Board is shrinking from 7 to 6 directors. All current directors except the founder are standing for election:

Filippo "Peter" Caldini (61): CEO since March 2025. Background in pharma/consumer health (Pfizer, Bayer, cannabis).
Ann Custin (66): Director since 2020. Former CFO of Siemens Medical Solutions. Healthcare finance expert.
Leslie Gillin (56): Director since 2021. Current CCO at Newrez. Former CMO at JPMorgan Chase. Marketing & growth expert.
Nicholas Lewin (48): Chairman since 2017. Private investor, focus on innovative tech/IP.
Edward Schutter (74): Director since 2015. Former CEO of Arbor Pharmaceuticals. Pharma industry veteran.
Bryan Slotkin (53): Director since 2020. Partner at PJT Partners (investment bank). Finance expert.

Juan José Chacón Quirós (54): Founder & former CEO (retired March 2025), is not standing for re-election and will leave the board after the meeting.

Key Changes: The board is declassifying (moving to annual election of all directors). This is the final step, with the last class (Class II) up for election this year.

💰 Executive Compensation (Proposals 1 & 2)

Named Executive Officers (NEOs) for 2025: Filippo "Peter" Caldini (CEO), Juan José Chacón Quirós (Former CEO), Rajbir S. Denhoy (Former CFO), S. Ross Mansbach (General Counsel).
Philosophy: Mix of base salary, annual cash bonuses (based on company/individual goals), and long-term equity awards (stock options/RSUs) to align with shareholder interests.
Highlights (Summary Compensation Table):
- Caldini (2025): Total comp ~$9.1M (mostly stock/option awards reflecting his new CEO role).
- Chacón Quirós (2025): Total comp ~$4.3M (includes advisory/consulting payments post-retirement).
- Denhoy (2025): Total comp ~$1.3M (SVP, Global Strategy role after CFO).
- Mansbach (2025): Total comp ~$1.0M.
New CFO: Cassandra "Sandra" Harris appointed March 9, 2026 (her compensation will be in next year's proxy).
Director Pay (2025): Annual retainer $50k (+$50k for Chairman). Committee fees ($5k-$20k). Equity awards valued at ~$125k annually. Total comp ranged from ~$440k to ~$1.4M (Lewin includes consulting fees).

🔍 Auditor Ratification (Proposal 3)

The Audit Committee recommends shareholders ratify the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for 2026.
CBIZ has been the auditor since 2020. The Audit Committee is satisfied with their work.

⚖️ Corporate Governance & Structure

Board Independence: 4 of 7 current directors (Custin, Gillin, Schutter, Slotkin) are independent under Nasdaq rules. Caldini (CEO) and Lewin (Chairman) are not independent.
Leadership: Separate Chairman (Nicholas Lewin) and CEO (Filippo Caldini) roles.
Key Committees: Audit (Custin, Schutter, Slotkin), Compensation (Schutter, Custin, Gillin), Nominating/Governance (Gillin, Custin, Slotkin).
Committees Meet Regularly: Audit (4 meetings in 2025), Compensation (5), Nominating/Governance (3). Full Board met 8 times.
Shareholder Proposals for 2027: Deadline is December 11, 2026, for inclusion in next year's proxy. Nominations/other business for 2027 meeting must be submitted between January 22, 2027, and February 21, 2027.

🧠 The Analogy

Think of this proxy statement as the agenda and rulebook for the company's annual shareholder "family meeting." It tells you who's running for the "board of family advisors" (directors), how much the "chief family officers" (executives) are being paid for running the business, which accounting firm the family trusts to check the books, and the rules for how the meeting itself will run and what decisions can be made.

🧩 Final Takeaway

This proxy outlines the key votes for ESTA's 2026 annual meeting: electing a slightly smaller board (without its founder), approving executive pay (especially the new CEO's significant package), and ratifying the auditor. The move to a fully declassified board (annual director elections) is now complete. Shareholders should review the director backgrounds and executive compensation details before voting.

ESTA Board Shrinks to Six as Founder Steps Down